MAPT and Cognitive impairment: Several other strategies, including those targeting tau enzymes/PTMs, proteostasis network, immune response, tau aggregation, and general neuroprotection, were frequently evaluated against both pathological tau (25 to 46 evaluations) and cognitive deficits (15 to 24 evaluations), and a high proportion of them (>80%) showed therapeutic effects (Figure 7).